105 related articles for article (PubMed ID: 38763761)
1. Risk Factors for Teicoplanin-Associated Acute Kidney Injury in Patients with Hematological Malignancies: Focusing on Concomitant Use of Tazobactam/Piperacillin.
Morinaga Y; Tanaka R; Tatsuta R; Takano K; Hashimoto T; Ogata M; Hiramatsu K; Itoh H
Biol Pharm Bull; 2024; 47(5):988-996. PubMed ID: 38763761
[TBL] [Abstract][Full Text] [Related]
2. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Acute Kidney Injury in Patient Receiving Piperacillin - Tazobactam: A Hospital-based Study from Qatar.
Khan FY; Abdalhadi AM; Kazman R; Mudawi DS; Shariff K; Suliman A; Chaudhry HS; Sharma R; Elballat A; Yousif AB; Alshurafa A; Ata F
Acta Med Indones; 2021 Apr; 53(2):156-163. PubMed ID: 34251343
[TBL] [Abstract][Full Text] [Related]
4. Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study.
Oda K; Hashiguchi Y; Katanoda T; Nakata H; Jono H; Saito H
Microbiol Spectr; 2021 Sep; 9(1):e0035521. PubMed ID: 34346742
[TBL] [Abstract][Full Text] [Related]
5. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
Aslan AT; Pashayev T; Dağ O; Akova M
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
[TBL] [Abstract][Full Text] [Related]
6. Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study.
Kadomura S; Takekuma Y; Sato Y; Sumi M; Kawamoto K; Itoh T; Sugawara M
J Pharm Health Care Sci; 2019; 5():13. PubMed ID: 31210955
[TBL] [Abstract][Full Text] [Related]
7. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.
Okada N; Chuma M; Azuma M; Nakamura S; Miki H; Hamano H; Goda M; Takechi K; Zamami Y; Abe M; Ishizawa K
Eur J Clin Pharmacol; 2019 Dec; 75(12):1695-1704. PubMed ID: 31511938
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.
Workum JD; Kramers C; Kolwijck E; Schouten JA; de Wildt SN; Brüggemann RJ
J Antimicrob Chemother; 2021 Jan; 76(1):212-219. PubMed ID: 32944771
[TBL] [Abstract][Full Text] [Related]
10. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
Tai CH; Shao CH; Wang CC; Lin FJ; Wang JT; Wu CC
J Antimicrob Chemother; 2021 Jan; 76(2):499-506. PubMed ID: 33152760
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
Robertson AD; Li C; Hammond DA; Dickey TA
Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
[TBL] [Abstract][Full Text] [Related]
15. Frequency of Acute Kidney Injury Caused by Tazobactam/Piperacillin in Patients with Pneumonia and Chronic Kidney Disease: A Retrospective Observational Study.
Morimoto T; Nagashima H; Morimoto Y; Tokuyama S
Yakugaku Zasshi; 2017; 137(9):1129-1136. PubMed ID: 28867699
[TBL] [Abstract][Full Text] [Related]
16. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
17. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Ide N; Sato S; Sawaguchi K
Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
[TBL] [Abstract][Full Text] [Related]
18. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
[TBL] [Abstract][Full Text] [Related]
20. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Kobayashi R; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
J Microbiol Immunol Infect; 2018 Aug; 51(4):473-477. PubMed ID: 28690028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
